These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria. Castellani C; De Boeck K; De Wachter E; Sermet-Gaudelus I; Simmonds NJ; Southern KW; J Cyst Fibros; 2022 Nov; 21(6):908-921. PubMed ID: 36220763 [TBL] [Abstract][Full Text] [Related]
5. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Derichs N Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166 [TBL] [Abstract][Full Text] [Related]
6. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Kotha K; Clancy JP Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658 [TBL] [Abstract][Full Text] [Related]
7. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
8. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
9. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. Burgel PR; Southern KW; Addy C; Battezzati A; Berry C; Bouchara JP; Brokaar E; Brown W; Azevedo P; Durieu I; Ekkelenkamp M; Finlayson F; Forton J; Gardecki J; Hodkova P; Hong G; Lowdon J; Madge S; Martin C; McKone E; Munck A; Ooi CY; Perrem L; Piper A; Prayle A; Ratjen F; Rosenfeld M; Sanders DB; Schwarz C; Taccetti G; Wainwright C; West NE; Wilschanski M; Bevan A; Castellani C; Drevinek P; Gartner S; Gramegna A; Lammertyn E; Landau EEC; Plant BJ; Smyth AR; van Koningsbruggen-Rietschel S; Middleton PG J Cyst Fibros; 2024 Mar; 23(2):187-202. PubMed ID: 38233247 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy. Farley H; Poole S; Chapman S; Flight W Postgrad Med J; 2022 May; 98(1159):341-345. PubMed ID: 33452147 [TBL] [Abstract][Full Text] [Related]
11. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Shteinberg M; Taylor-Cousar JL Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32198216 [TBL] [Abstract][Full Text] [Related]
12. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)]. ; ; Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700 [TBL] [Abstract][Full Text] [Related]
13. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Aslam AA; Sinha IP; Southern KW Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921 [TBL] [Abstract][Full Text] [Related]